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SUPPLEMENTAL FIGURE CAPTIONS 
 
FIGURE S1. Classification of Type A and B neurons, and differences between callosal 
EPSPs in Type A and B neurons, Related to Fig. 1. (A) Classification of Type A and Type B 
neurons based on a combination of the sag and rebound in response to a -250 pA pulse, and the 
afterhyperolarization (AHP) following a +250pA current pulse. Type A neurons were classified 
as cells with combined values >6.5 mV (dotted line). (B) Application of TTX and 4-AP 
eliminates excitatory responses to optogenetic stimulation of callosal projections. (C) EPSP 
dynamics in simultaneously recorded Type A and B neurons in cases that failed to evoke circuit 
inhibition (n = 3 pairs). These experiments have a similar latency to EPSP peak as our other 
experiments (15.4 ± 2.1 msec in these experiments, compared to 13.8 ± 1.8 msec in our complete 
dataset; p = 0.64). In these experiments, the difference between the pattern of EPSPs in Type A 
and B neurons was also similar to our other experiments. Specifically, the ratio between the 
second and first response was 1.57 ± 0.57 in Type A cells, and 0.77 ± 0.13 and in Type B cells, 
compared to 1.25 ± 0.18 and 0.78 ± 0.15 respectively in our complete dataset. (D) Representative 
image of Type A (green) and Type B (red) neurons labeled with retrogradely transported 
fluorescent microspheres injected into the MD thalamus (red) and contralateral mPFC (green), 
respectively. (E) Current clamp responses of labeled Type A (coticothalamic, CT) and B 
(cortiocallosal, CC) neurons to injection of -250pA. (F) Optogenetic stimulation of callosal 
inputs elicit depressing EPSPs in labeled Type B (CC) neurons, but not in labeled Type A (CT) 
neurons.  
 
FIGURE S2. Blocking post-synaptic voltage-dependent Ca
2+
 channels and NMDARs does 
not alter EPSP dynamics in Type A neurons, Related to Fig. 2. (A) Application of mibefradil 
(5 M) + nimodipine (5 M) + AP5 (50 M) does not alter EPSP dynamics in Type A during 
optogenetic stimulation of callosal inputs (n = 4). (B) The paired-pulse ratio is not significantly 
different after applying these Ca
2+
 channel blockers (p = 0.19, n = 4). 
 
FIGURE S3. Blocking h-current has minimal effects on simulated EPSPs and spiking in 
Type A neurons, Related to Fig. 3. (A) ZD7288 (25 M) blocks Ih in Type A neurons. (B) 
ZD7288 (brown) has minimal effects on the current clamp responses of Type A neurons to 
injection of Type A or B current waveforms (averaged response shown in black, individual 
responses shown in gray). (C) The paired-pulse ratio during responses of Type A neurons to 
simulated EPSCs in these current waveforms is not significantly altered by blocking Ih current (p 
= 0.30 and 0.39 for Type A and B waveforms, respectively; n=4 cells). (D) Blocking Ih with 
ZD7288 also fails to significantly alter the amount of spiking in Type A neurons in response to 
scaled up, suprathreshold current waveforms (p = 0.79 and 0.13 for Type A and B waveforms, 
respectively; n=4 cells). 
 
FIGURE S4. Effects of blocking GABAARs on EPSPs, and measuring inhibitory inputs to 
Type A and B neurons, Related to Fig. 4. (A) A1: Picrotoxin (ptx; 10 M) blocks outward 
currents that follow optogenetic stimulation of callosal inputs and represent feedforward 
inhibition in Type A neurons. A2: Ptx application prolongs EPSPs in Type A neurons evoked by 
optogenetic stimulation of callosal inputs. Thick lines represent the averaged EPSPs before 
(black) and after (red) ptx application.  Before averaging, each EPSP trace was normalized by 
the average amplitude of control EPSPs in that cell. Thin lines show individual normalized 
responses. A3: Ptx significantly prolongs the decay time constant for callosal EPSPs in Type A 
neurons (n=4 cells; p<0.001 by repeated measures ANOVA). (B) The dynamics of callosal 
EPSPs in Type A neurons are not significantly altered by application of ptx (black). To avoid 
epileptiform discharges, the light power was reduced to ~0.2 mW/mm
2
, i.e. 10% of the typical 
power, for some of these experiments. Spikes during responses in ptx have been truncated. (C) 
Ptx does not significantly alter the paired-pulse ratio for Type A neuron responses to optogenetic 
stimulation of callosal inputs (p = 0.37, n=4 cells). (D) Inhibitory currents peak ~2 msec after 
excitatory currents during optogenetic stimulation of callosal inputs (p < 0.01). (E) The average 
distance between FSINs and Type A or B neurons during experiments to measure connectivity 
from FSIN to these two subtypes (p = 0.271). (F) Experimental design: We simultaneously 
recorded from a pair of Type A (red) and B (blue) neurons in SOM::Cre mice injected with virus 
to drive Cre-dependent ChR2-EYFP expression (orange). During optogenetic stimulation of 
ChR2-expressing SOM interneurons, we recorded simultaneous IPSCs in Type A and B neurons 
in voltage clamp at +10 mV (bottom). (G) The peak amplitude of SOM interneuron-mediated 
IPSCs (left) and the corresponding inhibitory charge transfer (right) were similar in Type A and 
B neurons (p = 0.6 and p = 0.8, respectively; n=7 pairs). 
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